A detailed history of Gts Securities LLC transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Gts Securities LLC holds 63,800 shares of BLUE stock, worth $31,900. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,800
Previous 82,800 22.95%
Holding current value
$31,900
Previous $105,000 40.95%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.85 - $1.26 $3,165 - $4,692
-3,724 Reduced 6.4%
54,436 $53,000
Q1 2024

May 15, 2024

SELL
$0.91 - $1.75 $49,197 - $94,610
-54,063 Reduced 48.17%
58,160 $74,000
Q4 2023

Feb 14, 2024

BUY
$1.32 - $4.83 $79,078 - $289,355
59,908 Added 114.51%
112,223 $154,000
Q3 2023

Nov 15, 2023

BUY
$3.02 - $4.05 $32,498 - $43,582
10,761 Added 25.9%
52,315 $159,000
Q2 2023

Aug 15, 2023

BUY
$2.79 - $5.03 $115,935 - $209,016
41,554 New
41,554 $137 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $38.6M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.